Navigation path

Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

N-(tert-butylcarbamoyl)-5-cyano-2-((4'-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)oxy)benzenesulfonamide

EU orphan designation number: EU/3/18/1982   
Active ingredient: N-(tert-butylcarbamoyl)-5-cyano-2-((4'-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)oxy)benzenesulfonamide
Indication: Treatment of pulmonary arterial hypertension
Sponsor: ATXA Therapeutics Limited
75 Avoca Park, Avoca Avenue, Blackrock, County Dublin, A94 N803, Ireland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
26/02/2018 Orphan designation EMA/OD/199/17 (2018)1249 of 22/02/2018